Preview

Regional blood circulation and microcirculation

Advanced search

Hemodynamic effects of the vasodilation in different vascular regions on patients with severe left ventricle systolic dysfunction

https://doi.org/10.24884/1682-6655-2018-17-1-32-38

Abstract

Objective. To determine the specificity of the vasodilation of isosorbide dinitrate (ID), nitric oxide (NO), inhaled iloprost (iIlo). Materials and methods. Study included 190 vasoreactivity tests (ID, NO or iIlo, Swan-Ganz catheter) performed in 124 candidates for heart transplantation. Results. In the ID group mean PAP decreased by 22.8±14.7 %, in the NO - by 5.9±17.4 %, in the iIlo - by 14.6±15 %, PAWP in the ID group decreased by 29±17 %, in the iIlo - by 3.9±27.2 %, but in NO PAWP increased by 11±33.7 %. When using NO, SVI decreased from 23.8±7.9 to 22.4±6.7 ml/m2. When using D, SVI increased by 29.2±27.7 %, as well as in the iIlo by 20.6±24.5 %. Conclusion. Selective vasodilation of pulmonary vessels by NO caused LV overload and a decrease in LV output.

About the Authors

A. E. Bautin
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation
Russian Federation


A. S. Yakovlev
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation
Russian Federation


D. A. Ryazantseva
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation
Russian Federation


N. D. Klypa
A. I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation


A. O. Marichev
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation
Russian Federation


D. M. Tashkhanov
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation
Russian Federation


S. V. Zayashnikov
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation
Russian Federation


N. V. Aram-Balyk
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation
Russian Federation


P. A. Fedotov
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation
Russian Federation


M. A. Bortsova
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation
Russian Federation


L. I. Karpova
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation
Russian Federation


V. L. Etin
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation
Russian Federation


V. S. Kucherenko
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation
Russian Federation


References

1. Баутин А. Е., Яковлев А. С., Ташханов Д. М. и др. Особенности фармакодинамики илопроста при ингаляционном введении пациентам с выраженной систолической дисфункцией левого желудочка // Анестезиология и реаниматология. - 2015. - Т. 60. - № 2. - С. 4-7 [Bautin A.E., Yakovlev A.S., Tashxanov D.M. et al. Specifics of inhaled iloprost pharmacodynamics in patients with severe left ventricular systolic dysfunction. Anesteziologiya i reanimatologiya. 2015;60(2): 4-7. (In Russ)].

2. Alzahri MS, Rohra A, Peacock WF et al. Nitrates as a Treatment of Acute Heart Failure. Cardiac Failure Review. Medical Media Communications, Ltd. T/A Radcliffe Cardiology; 2016;2(1):51. doi: 10.15420/cfr.2016:3:3.

3. Bocchi EA, Bacal F, Auler JC et al. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. The American Journal of Cardiology. 1994;74(1):70-72. doi: 10.1016/0002-9149(94)90496-0.

4. Elkayam U, Khan S, Mehboob A, Ahsan N. Impaired endothelium-mediated vasodilation in heart failure: Clinical evidence and the potential for therapy. Journal of Cardiac Failure. 2002;8(1):15-20. doi: 10.1054/jcaf.2002.31910.

5. Galrn N, Humbert M, Vachiery J et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2015;37(1):67-119. doi: 10.1093/eurheartj/ehv317.

6. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. European Respiratory Journal. 2008;31(4):891-901. doi: 10.1183/09031936.00097107.

7. Guazzi M, Galie N. Pulmonary hypertension in left heart disease. European Respiratory Review. 2012;21(126):338-346. doi: 10.1183/09059180.00004612.

8. Loh E, Stamler JS, Hare JM et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation. 1994;90(6):2780-2785. doi: 10.1161/01.cir.90.6.2780.

9. Mehra M., Kobashigawa J., Starling R. et al. Listing criteria for heart transplantation: International society for heart and lung transplantation guidelines for the care of cardiac transplant candidates - 2006. The Journal of Heart and Lung Transplantation. 2006;25(9):1024-1042. doi: 10.1016/j.healun.2006.06.008.

10. Ponikowski P, Voors AA., Anker SD. et al. the The Task Force for diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128.

11. Ryan D, Frohlich S, McLoughlin P. Pulmonary vascular dysfunction in ARDS Ann Intensive Care. 2014;4(1):1-11. doi: 10.1186/s13613-014-0028-6.

12. Sablotzki A, Hentschel T, Gruenig E. et al. Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur J Cardiothorac Surg. 2002;22(5):746-752. doi: 10.1016/s1010-7940(02)00488-8.

13. Sablotzki A, Hentschel T, Hofmann S et al. Inhaled aerosolized iloprost in the evaluation of heart transplant candidates-experiences with 45 cases. J Clin Anesth. 2006;18(2):108-113. doi: 10.1016/j.jclinane.2005.08.018.

14. Sharon A, Shpirer I, Kaluski E et al. High-dose iv isosorbidedinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol. 2000;36(3):832-837. doi: 10.1016/s0735-1097(00)00785-3.

15. Vizzardi E, Bonadei I, Rovetta R, D'Aloia A. When should we use nitrates in congestive heart failure? Cardiovasc Ther. 2013;31(1):27-31. doi: 10.1111/j.1755-5922.2012.00311.x.


Review

For citations:


Bautin A.E., Yakovlev A.S., Ryazantseva D.A., Klypa N.D., Marichev A.O., Tashkhanov D.M., Zayashnikov S.V., Aram-Balyk N.V., Fedotov P.A., Bortsova M.A., Karpova L.I., Etin V.L., Kucherenko V.S. Hemodynamic effects of the vasodilation in different vascular regions on patients with severe left ventricle systolic dysfunction. Regional blood circulation and microcirculation. 2018;17(1):32-38. (In Russ.) https://doi.org/10.24884/1682-6655-2018-17-1-32-38

Views: 925


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1682-6655 (Print)
ISSN 2712-9756 (Online)